Skip to topic | Skip to bottom

Ús terapèutic del cannabis FICF ©

Fundació Institut Català de Farmacologia

Cannabis
[Darrera revisió: 16 Feb 2005 - 10:30]

Start of topic | Skip to actions

Ús terapèutic del cannabis: Bibliografia

Farmacologia bàsica

Key Description
1 Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003;2:291-8.
2 House of Lords Select Committee on Science and Technology. Ninth report on therapeutic uses of cannabis [en línea.]. 1998 novembre11 [accedit el dia 14 d'abril de 2001]; 40 (40). URL disponible en:
http://www.druglibrary.org/schaffer/Library/studies/hlords/15101.htm
3 Institute of Medicine. Marijuana and medicine [en línea]. 1999 [accedit el dia 14 d'abril de 2001]; 196. URL disponible a http://bob.nap.edu/books/0309071550/html
4 Williamson EM, Evans F. Cannabinoids in clinical practice. Drugs 2000; 60: 1303-14. Ref. SIETES
5 Ramos Atance JA, Fernández Ruiz J. Cannabinoides: propiedades químicas y aspectos metabólicos. Adicciones 2000; 12 (supl 2): 41-56.
6 S. Aquatias, J. Arditti, I. Bailly, M.B. Biecheler, M. Bouaboula, J.Coqus, I. i col·ls. Cannabis. Quels effets sur le comportement et la santé. Expertise collective INSERM París. INSERM (eds). 2001.
7 Hirst RA, Lambert DG, Notcutt WG. Pharmacology and potentcial therapeutic uses of cannabis. Br J Anaesth 1998; 81: 77-84.
8 Costa B, conti S, Giagnomi G, Colleoni M. the non-psychoactive cannabis constituent cannabidiol as anti-inflamatory drug in animal model in acute inflammation. Program and abstracts of the 12th Annual Symposium on the Cannabinoids [en línea] 2002 Juliol 10-14. California, USA [accedit el dia 17 d'agost de 2002]; 165 (44). URL disponible en http://www.cannabinoidsociety.org
9 Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andrakos E, Mechoulam R i col·ls. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000; 97: 9561-66.
10 Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE i col·ls. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 2004 (aprovat per publicar).
11 Massi P, Vaccani A, sacerdote P, Parolano D. Effects of cannbabidiol, a non psychoactive constituent of marijuana, on immune system. Program and abstracts of the 12th Annual Symposium on the Cannabinoids [en línea] 2002 Juliol 10-14. California, USA [accedit el dia 17 d'agost de 2002]; 165 (43). URL disponible en http://www.cannabinoidsociety.org
12 Parker AL, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002; 13: 567-70.
13 Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990; 253: 1002-09.
14 Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumor effects of cannabidiol, a non-psychotropic cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 2004; 308: 838-45.
15 Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982; 76: 245-50.
16 Karler R, Turkanis SA. The cannabinoids as potentcial antiepileptics. J Clin Pharmacol 1981; 21: 437S-48S.
17 Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 1981; 74: 208-12.
18 Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahllen A, Agurell S. Do plasma concentrations of 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 1981; 21: 171S-77S
19 Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-60.
20 Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B i col·ls. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br J Pharmacol 2000; 129: 1577-84.
21 Wilson DM, Peart J, Martin BR, Bridgen DT, Byron PR, Lichtman AH. Physiochemical and pharmacological characterization of a Delta(9)-THC aerosol generated by a metered dose inhaler. Drug Alcohol Depend. 2002; 67: 259-67.
22 Se prueba el THC (drobabinol) inhaldo en un estudio con vultarios sanos. Butlletí de la IACM [en línea] 2003 octubre 14 [accedit el dia 29 d'octubre de 2003]; 1 (2). URL disponible a: http://www.acmed.org/spanish/download/IACM_Bull_es2000.txt
23 Estados Unidos: Aprobado el primer estudio clínico con cannabis vaporizado. Butlletí de la IACM [en línea] 2003 gener 5 [accedit el dia 15 de gener de 2004]; 1 (2). URL disponible a: http://www.acmed.org/spanish/download/IACM_Bull_es2000.txt
24 Gieringer D. Cannabis Vaporization: A Promising Strategy for Smoke Harm Reduction. J Can Ther 2001;1: 153-70.
25 Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J of Clin Pharmacol Ther 1996;34:446-452. Ref. SIETES
26 ElSohly MA. A suppository formulation for delivery of Δ9-THC using a prodrug. Program and abstracts IACM 2nd Conference on Cannabinoids in Medicine [en línea] 2003 setembre 12-13 [accedit el dia 27 de gener de 2004]; 1(30). URL disponible a: http://www.cannabis-med.org/Meeting/Oxford2004/home.htm
27 Estados Unidos: patentado un parche de cannabinoides. Butlletí de la IACM [en línea] 2000 octubre 5 [accedit el dia 3 de gener de 2002]; 1 (2). URL disponible a: http://www.acmed.org/spanish/download/IACM_Bull_es2000.txt
28 Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 2003; 93: 377-87.
29 Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.
30 GW Pharmaceuticals Home [en línea] [accedit el dia 3 d'abril de 2002]; 24. URL disponible a: http://www.gwpharma.com
31 Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83: 637-49.
32 Martín BR, Dewey WL, Harris LS, Belckner JS. Delta-9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs. J Pharmacol Exp Ther 1976; 196: 128-44.
33 Fernandez-Ruiz JJ, Rodríguez F, Navarro M, Ramos JA. Maternal cannabinoid exposure and brain development: changes in the ontogeny of dopamine neurons: Bartke A, Murphy LL (eds). Marihuana/cannabinoids: neurobiology and neurophysiology. Biochemistry and physiology of substance abuse. Boca Ratón (Florida): CRC Press 1992; 4: 119-64.
34 Perez-Reyes M, Wall ME. Presence of delta 9-tetrahydrocannabinol in human milk. N Engl med 1982; 307: 819-20.
35 Martindale. The Complete Drug Reference. The Pharmaceutical Press [en CD-ROM]. Versió 2.00.000. A: MICROMEDEX Healthcare Series User's Guide; 2002.
36 USP Pharmacopoeial Convention. USP-DI: Drug Information for the health care provider, 22nd ed. Englewood: MICROMEDEX Thompson Healthcare; 2002.
37 Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-64.
38 Munro S, Thomas KL, Abu-Shaar M. Molecular characterisation of peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
39 Pertwee RG. Cannabinoid receptors and pain. Progress in Neurobiology 2001; 63: 569-611.
40 Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-64.
41 Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
42 Fernández-Ruiz JJ, Berrendero F, Hernández ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci 2000; 23: 14-20.
43 Mailleux P, Vanderhaeghen JJ. Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate-putamen. An in situ hybridation study. Neurosci Let 1993; 156: 51-53.
44 Rodriguez de Fonseca F, Cebeira M, Ramos JA, Martín M, Fernández-Ruiz JJ. Cannabinoid receptor in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci 1994; 54: 159-70.
45 Rodríguez de Fonseca F, Gorriti MA, Fernández-Ruiz JJ, Palomo T, Ramos JA. Down-regulation of rat brain cannabinoid binding sites after chronic D9-tetrahydrocannabinol treatment. Pharmacol Biochem Behavior 1994; 47: 33-40.
46 Mechoulam R, Ben Shabat S, Hanus L, Fride E, Vogel Z, Bayewitch M i col·ls. Endogenous cannabinoid ligands-chemical and biological studies. J Lipid Mediat Cell Signal 1996; 14: 45-49.
47 Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR i col·ls. Identification of an endogenous 2-mono-glyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
48 Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE i col·ls. 2-arachidonil gliceril eter, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2000; 98: 3662-35.
49 Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-49.
50 Calignano A, Katona I, Desarnaud F, Giuffrida A, La Rana G, Mackie K, Freund TF, Piomelli D. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000; 408: 96-101.
51 Hanus L, Gopher A, Almong S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993; 36: 3032-34.
52 Facci L, Dal Toso, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide amd palmitoylethanolamide. Proc Natl Acad Sci USA 1995; 92: 3376-80.
53 Cravatt BF, Próspero García O, Siuzdak G, Giula NB, Henriksen SJ, Lerner RA. Chemical characterization of a family of brain lipids that induce sleep. Science 1995; 268: 1505-9.
54 Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernández Ruiz JJ i col·ls. Brain regional distribution of endocannabinoids: Implications for their biosyntesis and biological function. Biochem Biophys Res Commun 1999; 256: 377-80.
55 Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol 1998; 359; 1-18.
56 Rodriguez de Fonseca F. El sistema cannabinoide como nueva diana terapèutica En: Conferència inaugural de la Societat Catalana de Farmacologia. Acadèmia de Ciències Mèdiques 15 d'octubre de 2002.
57 Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and sensitive method for its quantification in rat tissues. FEBS Lett 2002; 513: 294-98.
58 Giuffrida A. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298: 7-14.
59 Fowler CJ. Fatty acid amide hydrolase: biochemistry, pharmacology and therapeutic possibilities for an enzyme hydrolysing anandamide, 2- arachidonoylglycerol, palmitoylethanol-amide, and oleamide. Biochem Pharmacol 2001; 62: 517-26.
60 Bradbury J. Small part of cannabis puzzle solved by animals studies. Lancet 2001; 358: 302. Ref. SIETES
61 Gurwitz D, Weizman A. Fatty acid amide hydrolase inhibitors and the marijuana debate. Lancet 2001; 358: 1548.
62 Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997; 277: 1094-97.
63 Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Lastres-Becker I, Gonzalez S, Fernandez-Ruiz J i col·ls. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J Med Chem. 2001; 44: 4505-8.
64 Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs. 2000; 9: 1553-71.
65 Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A i col·ls. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-2.
66 Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Perez-Rosado A, Manzanares J. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 2002; 44: 23-35.
67 Gaetani S, Cuomo V, Piomelli D Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med. 2003; 9: 474-78.
68 Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H. Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 1996; 19: 1109-11.
69 Pérez-Reyes M, Burstein SH, White WR, Mc Donald SA, Hicks RE. Antagonism of marihuana effects by indomethacin in humans. Life Sci 1991; 48: 507-15.
70 Childers SR, Breivogel CS. Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 1998; 51: 173-87.
71 Ramos Atance JA, Fernández Ruiz J. Sistema cannabinoide endógeno: ligandos y receptores acoplados a mecanismos de transducción de señales. Adicciones 2000; 12 (supl 2): 59-81.
72 Szolcsányi J. Anandamide and the question of its funcional role for activation of capsaicin receptors. Trends Pharmacol Sci; 21: 203-04.
73 Piomelli D, Giuffrida A, Calignano A, Rodríguez de Fonseca F. The endocannabinoid system as target for therapeutic drugs. Trends Pharmacol Sci 2000; 21: 218-24.
74 Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58: 315-48.
75 Porter AC, Felder CC. The endocannabinoid nervous sistem. Unique opportunities for therapeutic intervention. Pharmacol Ther 2001; 90: 45-60.
76 Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000; 108: 169-90.
77 Klein TW. Cannabinoid receptors and immunity. Immunol Today 1998; 19: 373-81.
78 Kunos G, Jarai Z, Batkai S, Goparaju SK, Ishac EJ, Liu J, Wang L, Wagner JA. Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 2000; 108; 159-68.
79 Paria BC, Dey SK. Ligand-receptor signalling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids 2000; 108; 211-20.
80 Giuffrida A, Piomelli D. The endocannabinoid system: a physiological perspective on its role in psicomotor control. Chem Phys Lipids; 2000; 108: 151-58.
81 Lichtman AH. SR141716A enhances spatial memory as assessed in a radial-arm maze task inrats. Eur J Pharmacol 2000; 404: 175-79.
82 Mechoulam R, Fride E, Hanus L, Sheskin T, DiMarzo V, Bayewitch M, Vogel Z. Anandamide may mediate sleep induction. Nature 1997; 389: 25-26.
83 Gardner EL. Cannabinoid interaccion with brain reward systems-the neurobiological basis of cannabinoid abuse. En: Murphy LL, Bertke A. Marijuana/cannabinoids: Neurobiology and neurophisiology. New York: NY: CRC Press; 1992; 275-35.
84 Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z i col·ls. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-25.
85 Kirkham TC, Williams CM. Endogenous cannabinoids and appetite. Nutrition Res Rev 2001; 14: 65-86.
86 Fride et al. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 2001; 419: 207-14.
87 Wagner JA, Jarai Z, Batkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol. 2001; 423: 203-10.
88 Wolf J, Kram F, wahn H, Wagner JA. Endogenous cannabinoids increase pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Program and abstracts of the 2nd conference on Cannabinoids in Medicine 12-13 setembre 2003 [accedit el dia 15 d'octubre de 2003]; 1 (30) URL disponible a: http://www.cannabismed.org/Meeting/cologne2003/reader.pdf
89 Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 1998; 76: 824-36.
90 Macarrone M, Valensisi H, Bari M, Lazzarin N, Romanini C, Finazzi-Agró A. Relation between decreased anandamide hydrolase concentrations in human lymphocites and miscarriage. Lancet 2000; 355: 1326-29.
91 Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Molec Med 2002; 8: 58-61.
92 Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A i co·ls. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003; 302: 84-8.
93 Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V i col.ls. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003;125: 677-87.
94 Lepicier P, Bouchard JF, Lagneux C, Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol. 2003;139: 805-15.
95 Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J i col·ls. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 2001; 7: 827-32.
96 Vigna SR. Cannabinoids and the gut. Gastroenterology 2003;125: 973-5.
97 Grotenhermen F, Müller-Vahl K. IACM 2nd Conference on Cannabionoids in Medicine. Expert Opinion Pharmacother 2003; 4: 2367-71.
98 Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A Exercise activates the endocannabinoid system. Neuroreport 2003; 14: 2209-11.
99 Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004; 89: 134-41.
100 Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK, et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol. 2001; 38: 2048-54.
101 Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3:745-55.
102 Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001; 48: 859-67.
103 Izzo AA, Capasso F, Costagliola A, Bisogno T, Marsicano G, Ligresti A, i col·ls. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 2003;125:765-74.
104 Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T i col·ls. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001;134: 563-70.
105 Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21(suppl 8-9): S320-26.
106 Tramèr MR, Carroll D, Campbell FA, Reynolds JM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16-21. Ref. SIETES
107 Jochimsen PR, Lawton RL, VerSteeg K, Noyes Jr R. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther 1978; 24: 223-27.
108 Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978; 23: 397-401.
109 Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH i col·ls. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomised, placebo-controlled, phase II clinical trial. Crit Care Med 2002; 30: 548-54.
110 Lavon I, Sheinin T, Meilin S, Biton E, Weksler A, Efroni G i col·ls. A Novel Synthetic Cannabinoid Derivative Inhibits Inflammatory Liver Damage via Negative Cytokine Regulation. Mol Pharmacol 2003; 64: 1334-41.
111 Hanus L, Breuer A, Tchilibon S, Goldberg D, Horowitz M, Pertwee RG i col·ls. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96: 1428-33.
112 Anònim. Cannabis-like compound for neuropathic pain. Scrip 2003; 2872; 23. Ref. SIETES
113 Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, i col·ls. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350; 240-44.
114 Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C I col·ls. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284: 644-50.
115 Perz-Reyes M. The psychologic and physiologic effects of active cannabinoids. A: Nahas G, Sutin KM, Harvey DJ, Agurell S (eds), Marihuana and medicine. Totowa, NJ: Humana Press, 1999: 245-52.
116 Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38: 151-78.
117 Kirby MT, Hampson RE, Deadwyler SA. Cannabinoids selectively decrease paired-pulse facilitation of perforant path synaptic potentials in the dentate gyrus in vitro. Brain Res 1995; 688: 114-20.
118 Nakamura, E.M, Da Silva, E.A., Concilio, G.V, Wilkinson, D.A, Masur, J. Reversible effects of acute and long-term administration of delta9- tetrahydrocannabinol on memory in the rat. Drug Alcohol Depend 1991; 28: 167-75.
119 Reibaud M, Obinu MC, Ledent C, Parmentier M, Böhme GA, Imperato A. Enhancement of memory in cannabinoid CB1 receptor knockout mice. Eur J Pharmacol 1999; 379: R1-R2.
120 Marsiciano G. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-34.
121 Pertwee RG, Wickens AP. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 1991; 30: 237-44.
122 Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004; 73: 109-19.
123 Drummer OH, Gerostamoulos J, Batzirs H, Chu M, Caplehorn J, Robertsn MD, Swann P. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev 2004; 36: 239-48.
124 Bates MN, blakey TA. Role of cannabis in motor vehicle crashes. Epidemiol Rev 1999; 21: 222-32.
125 Longo MC, Hunter CE, Lokan RJ, White JM, White MA. The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability. Part II: the relation between drug prevalence and drug concentration, and driver culpability. Accid Anal Prev 2000; 32: 623-32.
126 Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 1999; 143: 315-17.
127 Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z i col·ls. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-25.
128 Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J i col·ls. An anorexic lipid mediator regulated by feeding. Nature 2001; 414: 209-12.
129 Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I i col·ls. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-17.
130 Cuerda MC, Bretón I, Cambor M, García P. Modulación farmacológica del apetito. Nutr Hosp 1998; 13: 69-75.
131 Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 2001; 11: 419; 207-14.
132 Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS I col·ls. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001; 121: 767-74.
133 Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995; 73: 907-10.
134 Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 2003; 166:156-62.
135 Parker LA, Kwiatkowska M, Burton P, Mechoulam R. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 2004;171:156-61.
136 Kwiatkowska M, Parker LA, Burton P, Mechoulam R.A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacolgy 2004.
137 Ozyurt E, Graham DI, Woodruff GN, McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 1988; 8: 138-43.
138 Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1-20.
139 Pacifici R, Zuccaro P, Pichini S, Roset PN, Poudevida S, Farre M i col·ls. Modulation of the immune system in cannabis users. JAMA 2003; 289: 1929-31. Ref. SIETES
140 McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS. Delta(9) tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther. 2002; 302: 451-65.
141 Zurier RB. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 2003;88:462-6.
142 Coates RA, Farewell VT, Raboud J, Read SE, MacFadden DK, Calzavara LM i col·ls. Cofactors of progression to acquired immunodeficiency syndrome in a cohort of male sexual contacts of men with human immunodeficiency virus disease. Am J Epidemiol 1990; 132: 717-22.
143 Kaslow RA, Blackwelder WC, Ostrow DG, Yerg D, Palenicek J i col·ls. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. A report from the Multicenter AIDS Cohort Study. JAMA 1989; 261: 3424-29.
144 Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol to asthmatic patients. Thorax 1976; 31: 720-23.
145 McCallum RW, Soykan I, Sridhar KR, Ricci DA, Lange RC, Plankey MW. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999; 13: 77-80.
146 Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophtalmol 1998; 116: 1433-37.
147 Anónimo. Marijuana speeds up sperm. Lancet 2003; 362: 1293. Ref. SIETES
148 Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004; 64: 1943-50.
149 Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6: 313-19.
150 Bornheim LM, Everhart ET, Li J, Correia MA. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol 1994; 48: 161-71.
151 Agrawal AK, Kumar P, Gulati A, Seth PK. Cannabis induced neurotoxicity in mice: effect of cholinergic (muscarinic) receptors and blood barrier permeability. Res Commun Subst Abuse 1989; 10: 155-68.
152 Murphy LL, Steger RW, Smith MS, Bartke A. Effects of 9tetrahydrocannabinol, cannabinol, cannabidiol, alone and in combination on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology 1990; 52: 316-21.

Indicacions en oncologia

Key Description
1 Allan SG. Mechanisms and management of chemotherapy induced nausea and vomiting. Blood Rev 1987;1: 50-57.
2 Morrow GR. The assesment of nausea and vomiting: post problems, current issues and suggestions for future research. Cancer 1984; 53: 2267-78.
3 Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence based, clinical practice guidelines. J Clin Oncol 1999;17:2971-94.
4 Lindley CM, Hirsh JD. Oncology nurses attitudes, percepcions, and knowledge of quality of life assessment in patients with cancer. Oncol Nurs Forum 1994; 21: 103-08.
5 Lecomte S, Leménager M, Duquenne L, Crepin G, Bonneterre J. Quality of life in breast cancer patients receiving adjuvant chemotherapy. Proc Annu Meet Am Soc Clin Oncol 1995;14: 308.
6 Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health related quality of life. Support Care Cancer 1997; 5: 307-13.
7 Morrow GR. Chemotherapy-related nausea and vomiting: etiology and management. Cancer 1989; 39: 89-04.
8 Alba E, Bastus R, de Andrés L, Sola C, Paredes A, López JJ. Anticipatory nausea and vomiting. Prevalence and predictors in chemotherapy patients. Oncology 1989; 46: 26-30.
9 Arlandis JL, Torres Jimenez NV. Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy. Ann Pharmacother 2000; 34: 573-79.
10 Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-09.
11 Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982; 307: 1476-80.
12 Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984; 10: 1170-75.
13 Kwong HNG. Chemotherapy-induced delayed emesis: what is the role of 5-HT3 antagonists. J Pharm Technol 2003; 19: 287-97.
14 Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Cancer 1995; 76: 343-57.
15 Aapro E, Setak M, Lichinister D et al. Palonosetron ( PALO) is more effective than ondansetron in preventing chemotherapy-induced nausea and voliting in patients receiving moderately emetogenic chemotherapy. Results of a Phase III trial. Proc Am Soc Clin Oncol 2003; 22: 726.
16 Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for prevention of chemotherapy-induced nausea and vomiting: a multinational randomized double-blind placebo-controlled trial in patients recibing hig-dose cisplatin. The aprepitant protocol 052 Study Group. J clin Oncol 2003; 21: 4112-19.
17 Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001; 121: 767-74.
18 Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995; 73: 907-10.
19 Soderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav 2001; 69: 343-50.
20 Kwiatkowska M, Parker LA, Burton P, Mechoulam R.A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacolgy 2004.
21 Parker AL, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis, and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002; 13: 567-70.
22 Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 2003; 166:156-62.
23 Parker LA, Kwiatkowska M, Burton P, Mechoulam R.Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 2004;171:156-61.
24 Musty RE, Rossi R. Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J CANT [en línea] 2001 [data d'accés el dia 5 de març de 2002]; 1: 29 (109). URL. Disponible a: http://www.cannabis-med.org/science-international/JCANT.btm
25 Vicinguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. NY State Med 1988; 88: 525-27.
26 Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323:16-21. Ref. SIETES
27 Jadad AR, Moore AR, Carrol D, Jenkinson C, Reynolds JM, Gavaghan J, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
28 Higi M, Niederle N, Bremer K, Schmitt G, Schmidt CG, Seeber S. Levonantradol bei der Behandlung von zytostatika-bedingter Übelkeit und Erbrechen. Dtsch Med Wschr 1982; 107: 1232-34.
29 Niiranen A, Mattson K. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol 1987; 10: 325-29.
30 Citron ML, Herman TS, Vreeland F, Kransow SH, Fossieck Jr BE, Harwood S, et al. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 1985; 69: 109-12.
31 Roffman RA. The controlled substances therapeutic research act in the state of Washington. J Clin Pharmacol 1981; 8-9(Suppl): 133S-40S.
32 Cunningham D, Forrest GJ, Soukop M, Gilchrist NL, Calder IT. Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs. BMJ 1985; 291: 864-65.
33 Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 1988; 24: 685-89.
34 Gilbert CJ, Ohly KV, Rosner G, Peters WP. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 1995; 76: 2330-37.
35 Priestman SG, Priestman TJ, Canney PA. A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea. Clin Radiol 1987; 38: 543-44.
36 Lucraft HH, Palmer MK. Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy induced vomiting. Clin Radiol 1982; 33: 621-22.
37 Lewis IH, Campbell DN, Barrowcliffe MP. Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. Br J Anaesth 1994; 73: 244-46.
38 Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manag 1995; 10: 89-97.
39 Ekert K, Waters KD, Jurk IH, Mobilia J, Loughnan P. Amelioration of cancer chemotherapy induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aus 1979; 2: 657-59.
40 Garb S, Beers AL, Bograd M, McMahon RT, Magalik A, Ashmann A, et al. Two-pronged study of tetrahydrocannabinol (THC) prevention of vomiting from cancer chemotherapy. IRCS Med Sci 1980; 8: 203-04.
41 Stambaugh Jr JE, McAdams J, Vreeland F. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. J Clin Pharmacol 1984; 24: 480-85.
42 Levitt M, Wilson A, Bowman D, Kemel S, Krepart G, Marks V, et al. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. J Clin Pharmacol 1981; 21: 103-19S.
43 Einhorn LH. Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy. Cancer Treat Rev 1982; 9(Suppl B): 55-61.
44 Lane M, Smith FE, Sullivan RA, Plasse TF. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol 1990; 13: 480-4.
45 Orr LE, McKernan JF. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 1981; 21: 76S-80S.
46 Ungerleider JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, Jamison K. THC or compazine for the cancer chemotherapy patient. The UCLA study. Part II: patient drug preference. Am J Clin Oncol 1985; 8: 142-47.
47 Ahmedzai S, Carlyle DL, Calder IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983; 48: 657-63.
48 Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987; 79: 946-52.
49 Chang AE, Shiling DJ, Stillman C, Goldberg NH, Seipp CA, Barofsky I, et al. Delta-9-tetrahydrocannabinol as antiemetic in cancer patients receiving high dose methotrexate. Ann Intern Med 1979; 91: 819-24.
50 Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981; 47: 1746-51.
51 Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and hiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 1980; 91: 449-51.
52 Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 1986; 3: 39-42.
53 Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986; 61: 502-05.
54 Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 1981; 21: 64S-69S.
55 Colls BM. Cannabis and cancer chemotherapy. Lancet 1980; I: 1187-88.
56 Frytak S, Moertel CG, Fallon JR, Rubin J, Creagan ET. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 1979; 91: 825-30.
57 George M, Pejovic MH, Thuaire M, Kramar A, Wolff JP. Randomized comparative trial of a new antiemetic, nabilone, in cancer patients treated with cisplatin. Biomed Pharmacother 1983; 37: 24-27.
58 Gralla RJ, Tyson LB, Bordin LA, Clark RA, Kelsen DP, Kris MG, et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rev 1984; 68: 163-72.
59 Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979; 300: 1295-97.
60 Hutcheon AW, Palmer JB, Soukop M, Cunningham D, McArdle C, Welsh J, et al. A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 1087-90.
61 Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 1982; 9: 25-33.
62 Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev 1982; 9: 45-48.
63 Kluin-Neleman JC, Neleman FA, Meuwissen OJAT, Maes RAA. Delta9-tetrahydrocannabinol (THC) as an antiemetic for patients receiving cancer chemotherapy; a double blind cross-over trial against placebo. Vet Hum Toxicol 1979; 21: 228-40.
64 Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manag 1991; 6: 352-59.
65 Levitt M. Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev 1982; 9(suppl B): 49-53.
66 McCabe M, Smith FP, MacDonald JS, Woolley PV, Goldberg D. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 1988; 6: 243-46.
67 Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 1981; 21: 38S-42S.
68 Niederle N, Schutte J, Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 1986; 64: 362-65.
69 Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985; 8: 336-40.
70 Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 1980; 140: 1431-33.
71 Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 1986; 17: 285-88.
72 Sallan SE, Zinberg NE, Frei E 3rd. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293: 795-97. Ref. SIETES
73 Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9- tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302: 135-38.
74 Steele N, Gralla RJ, Braun Jr DW, Young CW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980; 64: 219-24.
75 Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer therapy: a comparison of delta-9-THC and prochlorperazine. Cancer 1982; 50: 636-45.
76 Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind, randomized, crossover trial of nabilone vs placebo in cancer chemotherapy. Cancer Treat Rev 1982; 9(Suppl B): 39-44.
77 Levitt M, Faiman C, Hawks R, Wilson A. Randomized double blind comparison of delta-9-tetrahydrocannabinol (THC) and marihuana as chemotherapy antiemetics. ASCO Abstracts 1984; 3: 91.
78 Kris MG. Why do we need another antiemetic? Just Ask. J clin Oncol 2003; 21: 4077-80 .
79 Hickok JT, Roscoe JA, Morrow GR, King DV, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-Hydroxytryptamine-3 Antiemetics. Cancer 2003; 97: 2880-6.
80 Lindley C, Blower P. Oral serotonina type 3-receptor antagonists for prevention of chemotherapy-induced emesis. AM J Health Syst Pharm 2000; 57: 1685-97.
81 Chua DT, Sham JST, Kwong DL, Kwok CCH, Yue A, Foo YC et al. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for prevention of cisplatin-induced acute emesis. A randomised crossover study. Am J Oncol 2000; 23: 185-91.
82 Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting. Cancer 2000; 89: 2301-08.
83 Herrington JD, Kwan P, Young RR, Lagow E, Lagrone L, Riggs MW. Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Pharmacotherapy 2000; 20: 1318-23.
84 Hickocok JT, Roscoe JA, Morrow GR, Stern RM, Yang B, Flynn PJ, et al. Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. Cancer 1999; 86: 64-71.
85 Roscoe JA, Morrow GR, Hickock JT, Stern RM. Nausea and vomiting remain a significant clinical problem: Trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Management 2000; 20:113-21.
86 Iversen LL. Marihuana. Conocimiento científico actual. 1ª ed. Barcelona. Ariel; 2001: 185-94.

Indicacions en neurologia

Key Description
1 Pazos A, Pascual J.Farmacología de los movimientos anormales. Fármacos antiespásticos.A: Flórez J.Farmacología humana.3ª ed Barcelona, Masson; 1997: 513-63.
2 Noth J. Trends in the pathophysiology and pharmacotherapy of spasticity. J Neurol 1991;238:131-39.
3 Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000; 59: 487-95. Ref. SIETES
4 Gilman S, Newman SW, eds. Manter and Gatz's essentials of clinical neuroanatomy and neurophysiology, 9ª ed. Filadèlfia, Davis, 1996.
5 Anònim. Dantrolene sodium for treatment of spasticity. Med Lett Drugs Ther 1974; 16: 61-62.
6 Duncan GW, Shahani BT, Young RR. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. Neurology 1976; 26: 441-46.
7 Anònim. The management of spasticity. Drug Ther Bull 2000; 38: 44-46. Ref. SIETES
8 Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, et al. Cannabinoids control spasticity and tremor in multiple sclerosis model. Nature 2000; 404: 84-7.
9 Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM i col·ls. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126: 2191-20.
10 Achiron A, Miron S, Lavi V, Margalit R, Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000; 102: 26-31.
11 Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23: 2511-6.
12 Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF. Win 552122, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 2004: 10:158-64.
13 Di Marzo, V. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 21: 521-28.
14 Consroe P. Brain cannabinoid systems as targets for therapy of neurological disorders. Neurobiol Dis 1998; 5: 534-51.
15 Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of diskinesia in Parkinson's disease. Mov Disord 1998; 13: 871-76.
16 Aceto MD. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther 1998; 287: 598-605.
17 Di Marzo V, Bifulco M, De Petrocellis L. Endocannabinoids and multiple sclerosis: a blessing from the 'inner bliss'? Trends Pharmacol Sci 2000 ;21: 195-97.
18 Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38: 44-48.
19 Consroe P, Tillery W, Rein J, Musty RE. Reported marijuana effects in patients with spinal cord injury. Program and abstracts of the 8th Annual Symposium on the Cannabinoids 1998. Califòrnia, Estats Units.
20 Dunn M, Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia 1974;12: 175.
21 Malec J, Harvey RF, Cayner JJ. Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil 1982; 63: 116-18.
22 Anònim. UK cannabis to be legal for MS?.Scrip 1998; 2388: 4. Ref. SIETES
23 Simmons RD, Ponsonby AL, van der Mei IA, Sheridan P. What affects your MS? Responses to an anonymous, Internet-based epidemiological survey. Mult Scler 2004;10: 202-11.
24 Institute of Medicine. Marijuana and medicine [en línía.]. 1999 [accedit d'octubre de 2002]; 196. URL disponible a http://bob.nap.edu/books/0309071550/html
25 Grinspoon L, Bakalar JB. Marijuana: The Forbidden Medicine. New Haven, YaleUniversity Press, 1993.
26 Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996; 34: 446-52.
27 Schon F, Hart P, Hodgson TL, Pambakian ALM, Ruprah M. Supression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 1999; 53: 2209-10.
28 Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol. 1989; 236:120-22.
29 Jadad AR, Moore AR, Carrol D, Jenkinson C, Reynolds JM, Gavaghan J, McQuay HJ. Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1-12.
30 Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997; 126: 791-98.
31 Check WA. Marijuana may lessen spasticity of MS. JAMA. 1979; 241: 2476.
32 Ungerleider JT, Andrysiak T. Therapeutic issues of marijuana and THC (tetrahydrocannabinol). Int J Addict 1985; 20: 691-99.
33 Hamann W, Di Vadi PP. Analgesic effect on the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 1999; 353: 560. Ref. SIETES
34 Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983;13: 669-71.
35 Greenberg HS, Werness SAS, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994; 55: 324-28.
36 Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al. Cannabinoids for treatment of spasticity and other symptoms related to múltiple sclerosis (CAMS study): multicentre randomised placebo-controlled tial. Lacet 2003;362:1517-26. Ref. SIETES
37 Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9tetrahydrocannabinol. J Clin Pharmacol 1981; 21(8-9 Suppl): 413S-416S.
38 Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7: 39-50.
39 Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995; 345: 579.
40 Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58:1404-07.
41 Vaney C, Heinzel-Gutenbrunner M. Efficacy, safety and tolerability of an orally administered cannabis extract in treatment of spasticity in patients with múltiple sclerosis: a randomized, double blind, placebo-controlled, crossover study. Multiple sclerosis ECTRIMS 2003;9:S14.
42 Maurer M, Henn V, Dittrich A, Hofmann A. delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in single case doble-blind trial. Eur Arch Psychiatry Clin Neurosci 1990; 240: 1-4.
43 Hanigan WC, Destree R, Truong XT. The effect of 9-THC on human spasticity. Clin Pharmacol Ther 1986;39:198 (resum).
44 Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62:1105-09.
45 Brandy CM, DasGupta R, Wieman OJ, Berkley K, Fowler CJ. Acute and chronic effects of cannabis based medicinal extract on refractory lower urinary tract dysfunction in patients with advanced multiple sclerosis. J Neurol Neurosurg Psych 2002; 72: 139.
46 Anònim. GW Pharma begins further phase III cannabis trials. Scrip 2002; 2739:23.
47 Montané E. Revisión del tratamiento farmacológico de la espasticidad por enfermedad neurológica no progresiva. (Tesina de Doctorat). Universitat Autònoma de Barcelona. Barcelona, 2002.
48 Shakespeare DT, Young CA, Boggild M. Anti-spasticity agents for multiple sclerosis. (Cochrane Review). The Cochrane Library, Issue 4, 2000.
49 Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions forspasticity following spinal cord injury (Cochrane Review). The Cochrane Library, Issue 4, 2000.
50 Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31. Ref. SIETES
51 Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med 1997; 337:1604-11. Ref. SIETES
52 Rog D, Young CA. Randomized controlled trial of cannabis-based medicinal extracts in the treatment of neuropatic pain due to multiple sclerosis. Multiple sclerosis ECTRIMS 2003; 9: S25 (resum).
53 Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.

Tractament del dolor

Key Description down
64 Aguilera C, Arnau JM, Bosch C, Castel JM; Laporte JR, I Paredes, Vallano A, Farré M, Terán M, Menoyo E y Grupo de Estudio sobre la Analgesia Postoperatoria de la Sociedad Española de Farmacología Clínica. Analgésicos en el postoperatorio de intervenciones abdominales. Med Clin (Barc) 1997; 108: 136-40. Ref. SIETES
17 Anònim. Drug treatment of neuropathic pain. Drug Ther Bull 2000; 38: 89-93.
58 Anònim. GW Pharma begins further phase III cannabis trials. Scrip 2002; 2739: 23.
60 Anònim. GW Pharma to begin phase III cannabis trials. Scrip 2000; 2634: 6.
61 Anònim. GW's cannabis therapy for cancer pain. Scrip 2002; 2713. 22.
73 Anónim. Drug treatment of neuropathic pain. Drug Ther Bull 2000; 38: 89-93.
7 Ashburn MA, Staats PS. Management of chronic pain. Lancet 2001; 357: 1865. Ref. SIETES
63 Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003; 2: 291-98.
70 Bercovitch M, Walter A, Adunsky A. High dose morphine use in the hospice setting: a database survey of patient characteristics and effect on life expectancy. Cancer 1999; 86; 871-77.
53 Berman J, Lee J, Cooper M, Cannon A, Sach J. Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Anaesthesia 2003;58:936-40.
67 Bosch M, Diogène E, laporte JR. Índex Farmacològic 2000 5ª ed. Barcelona: Acadèmia de Ciències Mèdiques de Catalunya i de Balears; 2000: 113.
42 Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 1992; 49 (suppl 2): 35-42.
56 Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003;106:169-72.
6 Carr DB, Goudas LC. Acute pain. Lancet 1999; 353: 2051-58.
8 Cerveró F, Laird JMA. Fisiología del dolor. En Aliaga L. Baños JE, Barutell C et al (eds). Tratamiento del dolor: teoría y práctica. Barcelona, MCR 1995: 9-25.
27 Chatterjee A, Almahrezi A, Ware M, Fitzcharles MA. A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia. J Pain Symptom Manage 2002; 24: 4-6.
3 Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993; 52: 259-85.
41 Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 1998; 6: 534-51.
5 Costa D, Baños JE. Contribución del sistema nervioso central a la fisiología del dolor neuropático. Med Clin (Barc) 1993; 101: 591-95. Ref. SIETES
28 Dunn M, Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia 1974; 12:175.
33 Elsner F, Radbruch L, Sabatowski R. Tetrahydrocannabinol zur therapie chronischer schmerzen. Schmerz 2001; 15: 200-04.
62 Estados Unidos: Comienza un estudio con cannabis fumado en pacientes con neuropatía relacionada con sida. Butlletí de la IACM [en linea] 2002 abril 30 [accedit el dia 9 de juliol de 2002]; 1 (2). URL disponible a:
http://www.cannabismed.org/spanish/download/IACM_Bull_es2000.txt
30 García-Campayo J, Carrillo Sanz C, Ausejo Jiménez L, El-Khatib M. Efectividad del cannabis en el tratamiento del dolor somatomorfo. Aten Primaria 2002; 29; 140-41. Ref. SIETES
43 Gottschalk LA, Aronow WS, Prakash R. Effect of marijuana and placebomarijuana smoking on psychological satate and psychophysiological cardiovascular functioning in anginal patients. Biol Psychiatry 1977; 12: 255-66.
38 Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioural effects of smoked marijuana in humans. Drug Alcohol Depend 2000; 59: 261-75.
26 Grinspoon L, Bakalar JB. Marihuana: the forbidden medicine. Yale Univ Press 1993, New Haven CT (1997, edició revisada i ampliada. Trad. Marihuana: la medicina prohibida, Barcelona, Páidos 1997.
36 Hill SY, Goodwin DW, Schwin R, Powell B. Marijuana: CNS depressant of excitant? Am Psychiatry 1974; 131: 313-15.
51 Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997; 52: 483-86.
57 House of Lords Select Committe on Science and Technology. 2nd report on therapeutic uses of cannabis [en línea.]. 2001 març 14 [accedit el dia 21 de març de 2002]; 2(6). URL disponible en:
http://www.parliament.the-stationery-office.co.uk/pa/ld200001/ldselect/ldsctech/50/5002.htm
1 IASP Pain terms: a current list with definitions and notes on usage. Pain 1986; 3: S215-21.
39 Jadad AR, Moore AR, Carrol D, Jenkinson C, Reynolds JM, Gavaghan J, McQuay HJ. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. Ref. SIETES
46 Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21(suppl 8-9): S320-26.
50 Jochimsen PR, Lawton RL, VerSteeg K, Noyes Jr R. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther 1978; 24: 223-27.
45 Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE. Effects of delta9tetrahydrocannabinol and cannabinol in man. Pharmacology 1975; 13: 502-12.
55 Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA 2003; 290:1757-62. Ref. SIETES
13 Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 2003;103:175-86.
74 Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, Ellis RJ, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infeccion. Neurology 1998; 51: 1682-88.
72 Kost RG, Straus SE. Posttherpetic neuralgia. Phathogenesis, treatment and prevention. N Engl J Med 1996; 335: 32-42. Ref. SIETES
40 Kurzthaler I, Hummer M, Miller C, Sperner-Unterweger B, Gunther V, Wechdorm H, Battista HJ, Fleischhacker WW. Effect of cannabis use on cognitive functions and driving ability. J Clin Psychiatry 1999; 60: 395-99.
21 Lichtman AH, Martin BR. Cannabinoid-induced nociception is mediated by a spinal alpha-2-noradrenergic mechanism. Brain Reserch 1991; 559: 309-14.
2 Loeser JD, Melzack R. Pain: an overview. Lancet 1999; 353: 1607-09. Ref. SIETES
71 Low PA, Dotson RM. Symptomatic treatment of painful neuropathy. JAMA 1998; 280: 1863-64. Ref. SIETES
29 Lynch ME, Clark AJ. Cannabis reduces opioid dose in the treatment of chronic non cancer pain. J Pain Symptom Manage 2003; 25: 496-8.
23 Manzanares J, Corchero J, Romero J, Fernández-Ruiz J, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-93.
10 Martin BR, Lichtman A. Cannabinoid transmission and pain perception. Neurobiol Dis 1998; 5: 447-61.
12 Martin, W.J., Coffin, P.O., Attias, E., Balinsky, M., Tsou, K., Walker, J.M. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Research 1999; 822: 237-42.
52 Maurer M, Henn V, Dittrich A, Hofmann A. delta-9-tetrahydrocannabinol shows antiespastic and analgesic effects in single case doble-blind trial. Eur Arch Psychiatry Clin Neurosci 1990; 240: 1-4.
66 Mc Quay H. Opioids in pain management . Lancet 2001; 357 (S1): 37. Ref. SIETES
37 Milstein SL, MacCannell K, Karr G, Clark S. Marijuana produced changes in pain tolerance. Experienced and non experienced subjects. Int Pharmacopsychiatry 1975; 10: 177-82.
54 Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia. 2004; 59: 440-52.
34 Notcutt W, Prince M, Chapman G. Clinical experience with nabilone for chronic pain. Pharmaceut Sci 1997; 3: 551-55.
48 Noyes R, Brunk SF, Baram DA, Canter A. The analgesic properties of delta-9THC and codeine. Clin Pharmacol Ther 1975; 18: 84-89.
47 Noyes R, Brunk SF, Baram DA. The analgesic properties of delta-9tetrahydrocannabinol. Clin Pharmacol Ther 1975; 15: 139-43.
32 Oregon Medical Marihuana Program. [en linea] 2004 abril 1 [accedit el dia 20 de juny de 2004]; 1 (2). URL disponible a: http:// www.dhs.state.or.us/publichealth/mm/data.cfm
9 Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-11.
68 Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 353: 1695-700. Ref. SIETES
22 Puig SP, Ramos Atance JA. Cannabinoides: aspectos psiquiátricos y bioquímicos. En: Puig SP (ed). Consideraciones terapéuticas. Madrid, ediciones Rol S.A 2001: 141-42.
35 Raft D, Gregg J, Harris L. Effects of intravenous tetrahydrocannabinol of experimental and surgical pain. Psychological correlates of analgesic response. Clin Pharmacol Ther 1977; 21: 26-33.
18 Ramos Atance JA, Fernández Ruiz J. Sistema cannabinoide endògeno: ligandos y receptores acoplados a mecanismos de transducción de señales. Adicciones 2000; 12 (supl 2): 59-81.
11 Rice ASC. Cannabinoids and pain. Curr Opin Investig Drugs 2001; 2: 399-414.
59 Select committe on Homme Affairs. Memorandum 29. Submitted by GW Pharmaceuticals Plc (GW) [en línea] 2001 març 14 [accedit el dia 21 de març de 2002] 2(6). URL disponible en:
http://www.publications.parliament.uk/pa/cm200102/cmselect/cmhaff/318/318m40.htm
44 Sidell FB, Pless JE, Neitlich H, Sussman P, Copelan HW, Sim VM. Dimethylheptyl-delta 6a-10a-tetrahydrocannabinol: effects after parenteral administration to man. Proc Soc Exp Biol Med 1973; 142: 867-73.
49 Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978; 23: 397-401.
69 Stjernswärd J, Teoh N. Current status of the global cancer control program of the World Health Organization. J pain Symptom manage 1993; 8: 340-47.
4 Stubhaug A, Breivik H, Eide PK, Kreunen M, Foss A. Mapping of punctate hyperalgesia around a surgical incision demostrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand 1997; 41: 1124-32.
16 Szolcsányi J. Anandamide and the question of its funcional role for activation of capsaicin receptors. Trends Pharmacol Sci 2000; 21: 203-04.
65 Vallano A, Aguilera C, Arnau JM, Baños JE, Laporte JR. Management of postoperative pain in abdominal surgery in Spain. A multicentre drug utilization study. Br J Clin Pharmacol 1999; 47: 667-73. Ref. SIETES
19 Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptyc transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000; 57: 288-95.
20 Vaughan CW, Mc Gregor IS, Christie MJ. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 1999; 127: 935-40.
14 Wallace VC, Cottrell DF, Brophy PJ, Fleetwood-Walker SM. Local lysolecithininduced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci 2003; 23: 3221-33.
31 Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for choronic non-cancer pain: results of a prospective survey. Pain 2003;102: 211-16.
25 Welch SP, Stevens D. Antinociceptive activity of intrathecally administered cannabinoids alone and in combination with morfine in mice. J Pharmacol Exp Ther 1992; 262: 10-18.
24 Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O, Ozkan Y, et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003; 105: 303-8.
15 Zurier RB, Rosseti RG, Lane JH. Dimethylheptyl-THC-11oic acid. A nonpyschoactive antiinflamatory agent with a cannabinoid template structure. Arthritis Rheum 1998; 41: 163-70.

Indicacions en la Sida

Key Description
1 Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 1997; 315:1219-22.
2 Padilla GV. Psychological aspects of nutrition and cancer. Surg Clin North Am 1986; 66: 1121-35.
3 Palenicek JP, Graham NM, He YD, Hoover DA, Kingsley L, Saah AJ. Weight loss prior to clinical AIDS as a predictor of survival. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 366-73.
4 Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV associated wasting. Mayo Clin Proc 2000; 75: 386-94.
5 Carr A, Samaras K, Chisholm DJ, Cooper DA. Patogenesis of HIV-1-proteasa inhibitor associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-83. Ref. SIETES
6 Mantovani G, Macciò A, Massa E, Madeddu C. Managing cancer related anorexia/caquexia. Drugs 2001; 61: 499-514. Ref. SIETES
7 Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, i col.ls. Effects of thalidomide on HIV associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10: 1501-07.
8 Lissoni P, Paolorossi F, Tancini G, Barni S, Ardizzoia A, Brivio F i col.ls. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996: 32A: 1340-43.
9 Abel EL. Cannabis : effects on hunger and thirst. Behav Biol 1975; 15: 255-81.
10 Rodriguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, i col.ls. An anorexic lipid mediator regulated by feeding. Nature 2001; 414: 209-12.
11 Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, i col.ls. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-17.
12 Cuerda MC, Bretón I, Cambor M, García P. Modulación farmacológica del apetito. Nutr Hosp 1998; 13: 69-75.
13 Williams CM, Rogers PJ, Kirkham TC. Hyperphagia in pre-fed rats following oral Δ-9-THC. Physiol Behav 1998; 65: 343-46.
14 Crawley JN, Corwin RL, Robinson JK, Felder CC, Devane WA, Axelrod JA. Anandamide, an endogenous ligand of cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 1993;46: 967-72.
15 Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, i col.ls. Leptinregulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-25.
16 Kirkham TC, Williams CM. Endogenous cannabinoids and appetite. Nutrition Res Rev 2001; 14: 65-86.
17 Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive functions, neurotransmitter and corticosterone levels in dietrestricted mice. Eur J Pharmacol 2000; 392; 147-56.
18 Gardner EL. Cannabinoid interaccion with brain reward systems-the neurobiological basis of cannabinoid abuse. En: Murphy LL, Bertke A. Marijuana/cannabinoids: Neurobiology and neurophisiology. New York: NY: CRC Press; 1992; 275-35.
19 Rodriguez de Fonseca F. El sistema cannabinoide como nueva diana terapéutica En: Conferència inaugural de la Societat Catalana de Farmacologia. Acadèmia de Ciències Mèdiques 15 d'octubre de 2002.
20 Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 2001; 11: 419; 207-14.
21 Iversen LL. Marihuana. Conocimiento científico actual. 1ª ed. Barcelona. Ariel; 2001: 194-97.
22 Sydney S. Marijuana use in HIV positive and AIDS patients: Results of an anonymous mail survey. J CANT [en línia] 2001 [data d'accés: 5 de març de 2002]; 1: 1 (4). URL. Disponible a: http://www.cannabis-med.org/scienceinternational/JCANT(3-4).htm
23 Anònim. Uso de cannabis en el VIH. Butlletí de la IACM [en línea] 2003 Diciembre [accedit el dia 9 de decembre de 2003]; 1 (2). URL disponible a: http://www.cannabis-med.org/spanish/download/IACM_Bull_es2000.txt
24 Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 2004; 35: 38-45.
25 Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 1988; 11: 114.
26 Foltin RW, Fischman MW, Brandy JV. Behavioral analysis of marihuana effects on food intake in humans. Pharmacol Biochem Behav 1986; 25: 577-82.
27 Mattes RD, Engelman K, Shaw LM, Elsohly MA. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 1994; 49: 187-95.
28 Jadad AR, Moore AR, Carrol D, Jenkinson C, Reynolds JM, Gavaghan J, McQuay HJ. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. Ref. SIETES
29 Bruere E. Clinical management of anorexia and caquexia in patients with advanced cancer. Oncology 1992; 49 Suppl 2: 35-42.
30 Gorter R, Seefried M, Volberding P. Dronabinol effects on weight in patients with HIV infection. AIDS 1992; 6: 127.
31 Anònim. Put this in your pipe and smoke it: medicinal marijuana study. Treatmentupdate 2001; 12:19.
32 Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695-700.
33 Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994; 10: 14-18.
34 Jatoi A, Yamashita J, Sloan JA, Novotny PJ, Windschitl HE, Loprinzi CL. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group Investigation. Support Care Cancer 2002; 10: 71-75.
35 Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985; 8: 336-40.
36 Abrahams D, Leiser RJ, Shade SB, Hilton J, Elbeik T. Marijuana does not appear to alter viral loads of HIV patients taking protease inhibitors [en línia] 13 de juliol 2000 [accedit el 24 d'octubre de 2002] URL disponible a:
http://www.ucsf.edu/pressrel/2000/07/071302.html
37 Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14: 7-14.
38 Beal JE, Olson R, Laubenstein L, Morales JP, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manag 1995; 10: 89-97.
39 Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993; 27: 827-31.
40 Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G, and the DATRI 004 Study Group. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 1997; 13: 305-15.
41 Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA,i col.ls. Dronabinol versus megestrol acetate versus combination therapy for cancerassociated anorexia: a North Central Cancer Treatment Group Study. J Clin Oncol 2002; 15: 567-73.
42 Volicer L, Stelly M, Morris J,
McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 913-9.
43 Gurwitz K. Do endogenous cannabinoids contribute to HIV-mediated immune failure? Mol Med Today 1998; 196-200.
44 Gorter RW. Cancer caquexia and cannabinoids. Forsch Komplementärmed 1999; 6(supp 3): 21-22.
45 Lorenzo P, Leza JC. Utilidad terapéutica del cannabis y derivados. Adicciones 2000; 12 (supl 2): 149-68.
46 Di Franco MJ, Shepard HW, Hunter DJ. The lack of association of marihuana an other recreational drugs with progression to AIDS in San Francisco Men's Health Study. Ann Epidemiol 1996; 6: 283-89.
47 Whitfield RM, Bechtel LM, Starich GH. The impact of ethanol and Marinol/marijuana usage on HIV+AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytine, or dideoxyinosine therapy. Alcohol Clin Exp Res 1997; 21: 122-27.
48 Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams D. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002; 16: 543-50.
49 Regelson W, Butler JR, Schultz J, Kirk T, Peek L, Green Ml, Zalís MO. Tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. A: Braude MC, Szara S, eds. The pharmacology of marihuana. A monograph of the National Institute of Drug Abuse. New York: Raven, 1976; 763-76.
50 Strasser F, Lueftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W et al. Oral cannabis extract versus delta-9-tetrahydrocannabinol for patients with cancer related anorexia: a randomized, double blind placebo controlled multicenter study. Program and abstracts of the IACM 2nd Conference on Cannabinoids in Medicine [formato electrónico] 2003;35(20) [consultado 10-10-03]: Disponible en: http://www.acmed.org/spanish/nav/home-conference.htm
51 Suttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, Muller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatiens. J Aquir Immune Defic Syndr Hum Retrovirol 1995; 8: 239-46.
52 Chlebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritional status gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 1989; 84: 1288-93.
53 Smit E, Skolasky RL, Dobs AS, Calhon BC, Visschr BR, Palella FJ i col.ls. Changes in the incidence and predictors of wasting syndrome to human immunodeficiency virus infection, 1987-1999. Am J Epidemiol 2002; 156: 211-18.
54 Carbonnel F, Maslo C, Beaugerie L, Carrat F, Wirbel E, Aussel C i col.ls. Effect of indinavir on HIV-related wasting. AIDS 1998; 12: 1777-84.
55 Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998; 55: 675-88. Ref. SIETES

Altres indicacions

Key Description
1 Coleman AL. Glaucoma. Lancet 1999; 354: 1803-10. Ref. SIETES
2 Porcella A, Casellas P, Gessa GL, Pani L. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Brain Res Mol Brain Res 1998; 58: 240-45.
3 Laine K, Jarvinen K, Jarvinen T. Topically administered CB(2)-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits. Life Sci 2003; 72: 837-42.
4 Straiker AJ, Maguire G, Mackie K, Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci 1999; 40: 2442-48.
5 Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: Is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 1998; 243: 838-43.
6 Wagner JA, Varga K, Jarai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999; 33: 429-34.
7 Haefliger IO, Dettmann E, Liu R, Meyer P, Prunte C, Messerli J, Flammer J. Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma. Surv Ophthalmol 1999; 43: 51-58.
8 Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res 1997; 37: 3483-93.
9 Gebremedhin D, Lange AR, Campbell WB, Hilliard CJ, Harder DR. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 1999; 276: 2085-93.
10 Hepler RS, Frank IR. Marihuana smoking and intraocular pressure JAMA 1971; 217: 1392.
11 Flom MC, Adams AJ, Jones RT. Marijuana smoking and reduced pressure in humans eyes: drug action or epiphenomenon? Invest Ophthalmol 1975; 14: 5255.
12 Crowford WJ, Merrit JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int Clin Pharmacol Biopharm 1979; 17:191-96.
13 Merrit JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana intraocular and blood pressure in glaucoma. Ophthalmology 1980; 87: 222-28.
14 Merrit JC, McKinnon S, Armstrong JR, Hatem G, Reid LA. Oral 9tetrahydrocannabinol in heterogenous glaucoma. Ann Ophthalmol 1980; 12: 94750.
15 Jay WM, Green K. Multiple drop study of topically applied 1% tetrahydrocannabinol in human eyes. Arch Ophthalmol 1983; 101: 591-93.
16 Green K, Roth M. Ocular effects of topical administration of delta-9tetrahydrocannabinol in man. Arch Ophthalmol 1982; 100: 265-67.
17 Merrit JC, Perry DD, Russel DN, Jones BF. Topical delta-9-tetrahydrocannabinol and aqueous dynamics glaucoma. J Clin Pharmacol 1981; 21 (Suppl 8-9): 467S71S.
18 Porcella A, Maxia C, Gessa GL, Pani L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur J Neurosci 2001; 13: 409-12.
19 Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58: S2-S8.
20 Abood ME, Martin BR. Molecular neurobiology of cannabinoid receptor. Int Rev Neurobiol 1996; 39: 197-221.
21 Karler R, Calder LD, Sangdee P, i col.ls. Interaction between delta-9tetrahydrocannbinol and kindling by electrical and chemical stimulli in mice. Neuropharmacology 1984; 23: 1315-20.
22 Gordon E, Devinsky O. Alcohol and marijuana: Effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42: 1266-72.
23 Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 1998; 36: 189-97.
24 Consroe PF, Benedito MAC, Leite JR, Carlini EA, Mechoulam R. Effect of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982; 83: 293.
25 Wallance MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 2002; 452; 295-301.
26 Romero J. Sistema cannabinoide endógeno y epilepsia: nuevos retos. Sociedad Española de Investigación sobre Cannabinoides. Boletín electrónico [en linia] Juliol-setembre 2002; nº3. [accedit el 2 de desembre de 2002]; 2 (6). URL disponible a http://www.ucm.es/info/seic-web/boletin-3-2002.doc
27 Consroe PF, Wood GC, Buchbaum H. Anticonvulsant nature of marihuana smoking. JAMA 1975; 234: 306-07.
28 Ellison JM, Gelwan E, Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. Clin Psychiatry 1990; 51: 439-40.
29 Carlini EA, Cunha JM, Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981; 21 (Suppl 8-9): 417S-27S.
30 Ames FR. Anticonvulsant effect of cannabidiol. S Afr Med J 1986; 69: 14.
31 Karler R, Turkanis SA. The cannabinoids as potential antiepileptics. J Clin Pharmacol 1981; 21: 437S-48S.
32 Institute of Medicine. Marijuana and medicine [en línia.] 1999 [accedit el 2 de desembre de 2002]; 196. URL disponible a http://bob.nap.edu/books/0309071550/html
33 Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use. Dis Nerv Syst 1967; 28: 474-75.
34 Schapira AHV. Parkinson's disease. BMJ 1999; 318: 311-14.
35 Lastres Becker I, Cebreira M, de Ceballos M, Zeng BY, Jenner P, Ramos JA. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's disease amd MPTP treated marmosets. Eur J Neurosci 2001;14: 1827-32.
36 Frankel JP, Huges A, Lees AJ. Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 1990; 53: 436.
37 Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 1998; 5: 534-51.
38 Sieradzan KA, Fox SH, Mill M, Dick JPR, Crossman AR, Brotchie JM. Cannabinoids reduced levodopa induced dyskinesias Parkinson's disease. A pilot study. Neurology 2001; 57: 2108-11.
39 Fernández Ruiz JJ, Lastres Becker I, Cabranes A, González S, Ramos JA. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 263-73.
40 Glass M, Dragunow M, Faull RLM. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA-A receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000; 97: 505-19.
41 Denovan­Wright EM, Robertson HA. Cannabinoid receptor messenger RNA levels decrease in subset neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 2000; 98: 705-13.
42 Lastres Becker I, Cabranes A, De Lago E, Fernández Ruiz JJ. Cannabinoides y actividad motora. A: Guía básica sobre los cannabinoides. Sociedad Española de Investigación sobre cannabinoides [en línia] [accedit el 2 de desembre de 2002]; (8)159. Madrid 2002. URL disponible a: http://www.ucm.es/info/seic-web
43 Lastres Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A i col.ls. Changes in endocannabinoid transmission in the basal ganglia in rat model of Huntington's disease. Neuroreport 2001; 12: 2125-29.
44 Lastres Becker I, Hansen H, Berrendero F, DeMiguel R, Pérez-Rosado A, Manzanares G, i col.ls. Alleviaton of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in rat model of Huntington's disease. Synapse 2002; 44: 23-35.
45 Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, i col.ls. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991; 40: 701-08.
46 Muller-Vahl KR, Koblenz A, Jobges M, Kolbe H, Emrich HM, Schneider U. Influence of treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 2001; 34: 19-24.
47 Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res 1985; 5: 243-46.
48 Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1-20.
49 Calignano A, Katona I, Desarnaud F, Giuffrida A, La Rana G, Mackie K, i col.ls. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000; 408: 96-101.
50 Tashkin DP, Shapiro BJ, Lee YE, Harper CE. Effects of smoked marijuana in experimentally induced asthma. Am Rev Respir Dis 1975;112: 377-86.
51 Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis 1974;109: 420-28.
52 Tashkin DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW. Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy asthmatic subjects. Am Rev Respir Dis 1977; 115: 57-65.
53 Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of delta9tetrahydrocannabinol administered by aerosol to asthmatic patients. Thorax 1976; 31: 720-23.
54 Ahboud RT, Sanders HD. Effect of oral administraction of delta9-tetrahydrocannabinol on airway mechanisms in normal asthmatic subjects. Chest 1976; 70: 480-85.
55 Gong H, Tashkin DP, Calvarese B. Comparison of bronchial effects of nabilone and terbutaline in healthy and asthmatic subjects. J Clin Pharmacol 1983; 23: 127-33.
56 Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, Razdan RK, Martin BR. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br J Pharmacol 2000; 129: 1577-84.
57 Fabre LFR, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981; 21 (Suppl 8-9): 377S-82S.
58 Glass RM, Uhlenhuth EH, Hartel FW. The effects of nabilone, a synthetic cannabinoid on anxious human volunteers. Psychopharmacol Bull 1979; 15: 88.
59 Glass RM, Uhlenhuth EH, Hartel FW. Single dose study of nabilone in anxious volunteers. J Clin Pharmacol 1981; 21S: 383.
60 Nakano S, Gillespie HK, Hollister LE. A model for evaluation of antianxiety drugs with the use of experimentally induced stress: comparison of nabilone and diazepam. Clin Pharmacol Ther 1978; 23: 54-62.
61 Marsiciano G. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-34.
62 Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, i col.ls. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002; 97: 2117-19.
63 Ozyurt E, Graham DI, Woodruff GN, McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 1988; 8: 138-43.
64 Davalos A, Castillo J, Serena J, Noya M. Duration of glutamate release after acute ischemic stroke. Stroke 1997; 28: 708-10.
65 Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH i col.ls. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomised, placebo-controlled, phase II clinical trial. Crit Care Med 2002; 30: 548-54.
66 Sánchez C, Galve-Roperh I, Canova C, Brachet P, Guzmán M. Delta 9tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998; 436: 6-10.
67 Galve-Roperh I, Sánchez C, Cortés ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6: 313-19.
68 Guzmán M. Control de la decisión supervivencia/muerte celular por cannabinoides. Guía básica sobre los cannabinoies. Sociedad Española de Investigación sobre Cannabinoides [en línia] [accedit el 2 de desembre de 2002]; (4)159. Madrid 2002. URL disponible a: http://www.ucm.es/info/seic-web
69 Guzmán M. Cannabinoids: Potential anticancer agents. Nat Rev Cancer. 2003 Oct;3:745-55.
70 Antagonista de los receptores cannabinoides para la obesidad. Butlletí de la IACM [en linia] 2002 agost 14 [accedit el dia 9 de setembre de 2002]; 1 (2). URL disponible a: http:// www.cannabismed.org/spanish/download/IACM_Bull_es2000.txt
71 Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003; 64: 459-65.

Efectes indesitjats i interaccions

Key Description
1 Grinspoon L, Bakalar JB. Marihuana as medicine. A plea for reconsideration. JAMA 1995; 273: 1875-76. Ref. SIETES
2 Institute of Medicine. Marijuana and medicine [en línea] 1999 [accedit el dia 14 novembre de 2002]; 196. URL disponible a: http://bob.nap.edu/books/0309071550/html
3 Wayne H, Solowij N. Adverse effects of cannabis. Lancet 1998; 352: 1611-16.
4 Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83: 637-49.
5 Bovasso GB. Cannabis abuse as risk factor for depressive symptoms. Am J Psychiatry 2001; 158: 2033-37.
6 Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002; 325: 1195-98. Ref. SIETES
7 Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909-15.
8 Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123-31. Ref. SIETES
9 Grant I, Gonzalez R, Carey C, Natarajan L. Long-term neurocognitive consequences of marijuana: a meta-analytic study. A: National Institute on Drug Abuse Workshop on Clinical Consequences of Marijuana [en línea] Agost 13, 2001 [accedit el dia 8 de gener de 2003]; (1)11. URL disponible a: http://www.nida.nih.gov/MeetSum/marijuanaabstracts.html
10 Pope HG. Cannabis, cognition and residual confounding. JAMA 2002; 287; 117274. Ref. SIETES
11 Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997;126: 791-98. Ref. SIETES
12 Tramèr MR, Caroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2000; 323: 16-21. Ref. SIETES
13 Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982; 76: 245-50.
14 Dougherty DM, Cherek DR, Roache JD. The effects of smoked marijuana on progressive-interval schedule performance in humans. J Exp Anal Behav 1994; 62: 73-87.
15 Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38: 151-78. Ref. SIETES
16 Gunderson EW, Vosburg SK, Hart CL, Watson LTM, Nyquist JR, et al. Does marijuana use cause long-term deficits. JAMA 2002; 287: 2652-54. Ref. SIETES
17 Mc Kay DR, Tennant CC. Is the grass greener? The link between cannabis and psychosis. Med J Aust 2000; 172: 284-86.
18 Hall W, Degenhardt L. Cannabis and psychosis. Aust N Z J Psychiatry 2000; 34: 26-34.
19 Andreason S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1433-36.
20 Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325: 1199-201. Ref. SIETES
21 Rey JM, Tennant CC. Cannabis and mental health. BMJ 2002; 325; 1183-84.
22 Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, MoffittTE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212-23. Ref. SIETES
23 Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction. 2003; 98: 685-92.
24 Ghuran A, van der Wieken LR, Nolan J. Cardiovascular complications of recreational drugs. BMJ 2001; 323: 464-65. Ref. SIETES
25 Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1-20.
26 Mittelman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marihuana. Circulation 2001; 103: 2805-09.
27 Tashkin DR, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 2002; 42(11 Suppl): 71S-81S.
28 Tashkin DP, Coulson AH, Clark VA, Simmons M, Bourque LB, Duann S et al. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. Am Rev Respir Dis 1987; 135: 209-16.
29 Sridhar KS. Raub WA, Weatherby NL, Metsch LR, Surrat HL, Inciardi JA, et al. Possible role of marijuana smoking as a carcinogen in the devolopment of lung cancer at young age. J Psychoactive Drugs 1994; 26: 285-88.
30 Caplan GA, Brigham BA. Marijuana smoking and carcinoma of tongue. Cancer 1990; 66: 1005-90.
31 Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 1999; 8: 1071-78.
32 Henry JA, Oldfield WLG, Min Kon O. Comparing cannabis wuth tabaco. BMJ 2003; 326; 942-43.Ref. SIETES
33 Zhang ZF, Morgensten H, Spitz MR, Tashin DP, Yu GP, Marsshall JR et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer epidemiol biomarkers Prev 1999; 8: 1071-78.
34 Sidney S, quesenberry CP, Friedman GD, Tekawa IS: Marijuana use and cancer incidence.( California, United States). Cancer Causes Control 1997; 8: 722-28.
35 Klein TW, Newton C, Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998; 19: 373-81.
36 Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci 1999; 65: 637-44.
37 Di Franco MJ, Shepard HW, Hunter DJ. The lack of association of marihuana an other recreational drugs with progression to AIDS in San Francisco Men's Health Study. Ann Epidemiol 1996; 6: 283-89.
38 Whitfield RM, Bechtel LM, Starich GH. The impact of ethanol and Marinol/marijuana usage on HIV + AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytine, or dideoxyinosine therapy. Alcohol Clin Exp Res 1997; 21: 122-27.
39 Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H et al. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 1989; 320: 762-68. Ref. SIETES
40 Fried PA. Prenatal exposure to tobacco and marijuana: effects during pregnacy, infancy, and early chilhood. Clin Obstet Gynecol 1993; 36: 319-36.
41 Robison LL, Buckley JD, Daigle AE, Wells R, Benjamin D, Arthur DC et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. Cancer 1989; 63: 1904-11.
42 Hezode C, et al. Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Abstract 68. 39th Annual European Association for the Study of the Liver Conference, 14-18 de April de 2004. Berlín, Alemania; Grenard P, et al. Reduced liver fibrosis in CB1 receptor knockout mice. (resum) J Hepatology 2004; 40(S1): 8.
43 Hollister LE. Interactions of marihuana and 9-THC with other drugs. A: Nahas G, Sutin KM, Harvey DJ, Agurell S, eds. Marihuana and medicine. Totowa, NJ: Humana Press 1999; 273-77.
44 Sutin KM, Nahas GG. Physiological and pharmacological interations of marihuana (9-THC) with drugs and anesthetics. A: Nahas G, Sutin KM, Harvey DJ, Agurell S. Marihuana and medicine. Totowa, NJ: Humana Press, 1999; . 253-71.
45 Pryor GT, Husain S, Mitoma C. Acute and subacute interactions between delta-9tetrahydrocannabinol and other drugs in the rat. Ann N Y Acad Sci 1976; 281:171-89.
46 Manzanares J, Corchero J, Romero J, Fernández-Ruiz J, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-93.
47 Welch SP, Stevens D. Antinociceptive activity of intrathecally administered cannabinoids alone and in combination with morfine in mice. J Pharmacol Exp Ther 1992; 262: 10-18.
48 Carta G, Gessa GL, Nava F. Dopamine D(2) receptor antagonists prevent delta(9)-tetrahydrocannabinol-induced antinociception in rats. Eur J Pharmacol 1999; 384: 153-56.
49 Anikwue R, Huffman JW, Martin ZL, Welch SP. Decrease in efficacy and potency of nonsteroidal anti-inflamatory drugs by chronic 9-tetrahydrocannabinol administration. J Pharmacol Exp Ther 2002; 303: 340-46.
50 Moss DE, Manderscheid PZ, Montgomery SP, Norman AB, Sanberg PR. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 1989; 44:1521-1525.
51 Perez-Reyes M, Burstein SH, White WR, McDonald SA, Hicks RE. Antagonism of marihuana effects by indomethacin in humans. Life Sci1991; 48: 507-15.

Tolerància i dependència

Key Description
1 Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1-17.
2 Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacolgy 1999; 141: 385-94.
3 Maldonado R, Rodriguez de Fonseca F. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 2002; 22: 3326-31.
4 Pertwee R, Stevenson LA, Griffin G. Cross tolerance between delta-9tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55, 212-2 and anandamide. Br J Pharmacol 1993; 110: 1483-90.
5 Romero J, Garcia L, Fernandez Riuz JJ, Cebeira M, Ramos JA. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide or to delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav 1995; 51: 731-37.
6 Rubino T, Patrini G, Massi P, Fuzio D, Vigano D, Giogni G, Parolaro D. Cannabinoid precipitated withdrawal: a time course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998; 285: 813-19.
7 Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther 2002; 95: 153-64.
8 Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981; 21: 143S-52S.
9 Campbell FA, Tràmer MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ; 2001; 323: 13-16. Ref. SIETES
10 Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, i col.ls. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14: 7-14.
11 Tramèr MR, Caroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2000; 323: 16-21. Ref. SIETES
12 Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995; 345: 579.
13 Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9tetrahydrocannabinol. J Clin Pharmacol 1981; 21(Suppl 8-9): 413S-16S.
14 Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7: 39-50.
15 Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, i col.ls. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-07.
16 Newell FW, Stark P, jay WM, Schazlin DJ. nabilone : a pressure reducing synthetic benzopyran in open angle glaucoma. Ophthalmology 1979; 86: 156-60.
17 Diana M, Melis M, Muntoni AL, Gessa GL. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 1998; 95: 10269-73.
18 Aceto MD, Scates SM, Lowe JA, Martin BP. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, Win 55, 212-2. Eur J Pharmacol 2001; 416: 75-81.
19 Lichtman AH, Wiley JL, Lavecchia KL, Neviaser ST, Arthur DB, Wilson DM, i col.ls. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. Eur J Pharmacol 1998; 355: 139-48.
20 Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot , i col.ls. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knoockout mice. Science 1998; 283: 15-19.
21 Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F. Activation of corticotropin realising factor in limbic system during cannabinoid withdrawal. Science 1997; 276: 2050-54.
22 Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci 1992; 13: 201-02.
23 Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 1999; 141; 395-404.
24 James CA, Lynn A, Kessler W, Kessler R. Comparative epidemiology of dependence on tabacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharm 1994; 3: 244-68.



Copyright © 1999-2014 Fundació Institut Català de Farmacologia.
Comentaris o dubtes sobre aquest espai web? Envia un e-mail.